Salute e Benessere

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from April 21 to April 25, 2025: Trading Platform...
Nasdaq GlobeNewswire
28/04/2025

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response -…

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the precision of Evaxion's AI-Immunology™ platform in selecting therapeutically relevant vaccine targetsNew findings show EVX-01 inducing a robust and durable immune response, further enhanced by booster immunizationsThe ongoing phase 2 trial with EVX-01 remains on track for two-year data...
Nasdaq GlobeNewswire
28/04/2025

Nature Communications Medicine Publishes Positive, Real World Data for Tinnitus…

Results in the paper titled: "Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting" reported 91.5% of tinnitus patients had a clinically significant reduction in tinnitus. These real-world results are consistent with Lenire's clinical trial results that were instrumental in Lenire being granted De Novo approval by the FDA in March 2023 Results in the paper titled:"Retrospective chart review demonstrating…
PR Newswire
28/04/2025

Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel…

Study Presented at the Clinical Trials Plenary Session Study Presented at the Clinical Trials Plenary Session TEL AVIV, Israel , April 28, 2025 /PRNewswire/ -- Lutris Pharma , a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, presented data from its recently completed double-blind, placebo-controlled phase 2 randomized clinical trial of lead therapy, LUT014 gel, demonstrating...
PR Newswire
28/04/2025

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

AAVantgarde Bio(AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Mr. Rasmus Holm-Jorgesen as their Chief Financial Officer (CFO). Rasmus brings over 25 years of experience in strategy, finance and global operations within the biopharmaceutical industry to AAVantgarde and has joined the Company's leadership team, reporting to Dr Natalia...
Nasdaq GlobeNewswire
28/04/2025

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC…

LONDON and PHOENIX, Ariz., April28, 2025(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics and information company, are pleased to announce the expansion of their strategic partnership to include the commercialization of the MSC test for lung cancer screening. This collaboration aims to enhance the accuracy of lung nodule...
Nasdaq GlobeNewswire
28/04/2025

Annual Report 2024 released by Scantox Group

With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support. With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support. "We have in 2024 continued to demonstrate our commitment to expanding both…
PR Newswire
28/04/2025

Comac Medical Announces New Leadership Appointments and International Expansion

Leadership Appointments Leadership Appointments Dr. Chris Smyth has been appointed as Chief Executive Officer, effective 1 stSeptember. Based in the UK, Dr. Smyth brings over two decades of executive leadership in global CROs and biotech-focused clinical research. Most recently, he served as President of ICON Biotech, and prior to that, held multiple senior roles at IQVIA Biotech including President and COO. Comac Medical has also established a new Supervisory Board, chaired byNeil...
PR Newswire
28/04/2025

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar…

These recommendations follow a review of comprehensive data packages, including clinical studies results[1], which demonstrated comparability with the reference product in terms of pharmacokinetic, safety, efficacy and immunogenicity profiles. These recommendations follow a review of comprehensive data packages, including clinical studies results[1], which demonstrated comparability with the reference product in terms of pharmacokinetic, safety, efficacy and immunogenicity profiles. ...
PR Newswire
28/04/2025

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory…

Its lead asset, CUR-101, is a novel protein-based targeted therapy for acute myeloid leukaemia (AML). The therapeutic rationale underlying Cycuria's approach holds significant potential beyond its current focus on AML, potentially extending to other blood cancers as well as hard-to-treat solid cancers. Its lead asset, CUR-101, is a novel protein-based targeted therapy for acute myeloid leukaemia (AML). The therapeutic rationale underlying Cycuria's approach holds significant potential beyond...
PR Newswire
28/04/2025

Transactions under Novonesis' share buyback program

Please read the announcement in PDF Attachment 2025_20_Share_buyback_program
Nasdaq GlobeNewswire
28/04/2025

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive…

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025Glasgow, Scotland – 28 April 2025.EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA....
Nasdaq GlobeNewswire
28/04/2025

ILIKOS Consulting Group Accelerates International Growth with New Greek…

"We are thrilled to extend our presence into Greece, reflecting our dedication to promoting local talent and innovation ," stated Elias Sayias, Founder and CEO of ILIKOS Consulting Group. "This expansion aligns with our growth strategy and reinforces our commitment to empowering our Clients and community alike to achieve their growth objectives." "We are thrilled to extend our presence intoGreece, reflecting our dedication to promoting local talent and innovation,"…
PR Newswire
28/04/2025

ONWARD Medical Announces Release of 2024 Annual Report

The Company has also released its 2024 Sustainability Report. Last year, the Company was awarded a silver medal by EcoVadis, the world's largest provider of business sustainability ratings."2024 was transformative for ONWARD as we advanced our mission to restore movement, function, and independence for people with spinal cord injury," said Dave Marver, Chief Executive Officer. "We are pleased to share our progress and financial results with our stakeholders through our Annual…
Nasdaq GlobeNewswire
28/04/2025

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. Currently two…
PR Newswire
28/04/2025

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with…

"Ovarian cancer's characteristic peritoneal metastasis lead to frequent recurrences despite a comprehensive treatment approach," commented Dr. Luis Chiva, Principal Investigator and Director of Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Spain. "I am proud to be part of a study program exploring whether Radspherin® may become a novel therapy that can prevent disease progression, offering hope for a better and longer life for my patients."…
PR Newswire
28/04/2025

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug…

EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people in the European UnionPurespring has previously demonstrated the potential of PS-002, the Company's lead programme, as an important novel targeted treatment for primary IgANPS-002 is progressing towards a Phase I/II clinical trial, supported by a strong preclinical data packageLondon –...
Nasdaq GlobeNewswire
28/04/2025

LIfT BioSciences announces partnership with University of Galway for clinical…

LIfT BioSciences announces partnership with University of Galway for clinical trial in IrelandLondon,28 April 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces progress in advancing the planned clinical trial for their Immunomodulatory Alpha Neutrophils (IMANs), a first-in-class cell therapy designed to overcome treatment resistance in solid tumours, which will be conducted in partnership...
Nasdaq GlobeNewswire
28/04/2025

Sanitary and Bathroom Equipment Spotlighted at 137th Canton Fair Phase 2…

Designed to enhance modern living, the intelligent toilet series integrate advanced features for a more hygienic and enjoyable experience. Smart functions include self-diagnosis, foot-activated flushing, and an infinite-bit control knob. Cleanliness is prioritized through water purification, pre-wash capabilities, and a self-cleaning nozzle. For optimal comfort, features such as automatic flushing, hot and cold massage cleaning, and an air-cleaning filter system are included. Designed to...
PR Newswire
27/04/2025

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™…

The 12-month data from the Volt CE Mark Study were presented at the 2025 Heart Rhythm Society (HRS) annual meeting held in San Diego (April 24-27, 2025) and simultaneously published in Heart Rhythm, the official journal of the Heart Rhythm Society. The 12-month data from the Volt CE Mark Study were presented at the 2025 Heart Rhythm Society (HRS) annual meeting held inSan Diego( April 24-27, 2025 ) and simultaneously published inHeart Rhythm, the official journal of the Heart Rhythm Society...
PR Newswire
27/04/2025

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by…

Saint Herblain (France), April 26, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ ®for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing...
Nasdaq GlobeNewswire
26/04/2025

Financière de Tubize - Dividend approval

Dividend confirmation Regulated information - 25 april 2025The general shareholders meeting of 25 April 2025 has approved the annual accounts as at 31 December 2024, including the distribution of a gross dividend of € 1.04 per share.The dividend will be payable as from 5 May 2025 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 20.Ex-coupon 30 April 2025 Record date 2 May 2025 Payment date 5 May 2025
Nasdaq GlobeNewswire
26/04/2025

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtualCapital Markets Dayfor investors and analysts onTuesday, April 29, 2025.The event will highlight recent financial and clinical milestones and provide future strategic updates.The webcast, streamed...
Nasdaq GlobeNewswire
25/04/2025

Oculis Updates Share Capital

As a result, the total number of registered shares as set forth in the Company's Articles of Association has increased to 54,533,674. This increase has been registered with the Zug Commercial Register.For more information, please visit:http://www.oculis.comOculis Contact: Ms. Sylvia Cheung, [email protected] Investor & Media Relations: LifeSci Advisors Corey Davis, [email protected]
Nasdaq GlobeNewswire
25/04/2025
Altri  Comunicati